Search results
Results from the WOW.Com Content Network
N-Benzyl-2C-B (25B-NB, NB-2C-B) is a recreational designer drug from the 25-NB subgroup of the substituted phenethylamine family, with psychedelic effects. It has a binding affinity (K i ) of 16 nM at the serotonin receptor 5-HT 2A and 90 nM at 5-HT 2C and reportedly has a potency in between that of 2C-B and NBOMe-2C-B .
25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT 2A receptor .
The 25-NB (25x-NBx) series, or NBOMe series, also known as the N-benzylphenethylamines, is a family of serotonergic psychedelics. [ 1 ] [ 2 ] They are substituted phenethylamines and were derived from the 2C family . [ 2 ]
The N-benzyl derivative however was found to have higher binding affinity than 2C-B itself, with N-(4-bromobenzyl)-2CB binding even more tightly. [49] This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe, [50] and 25B-NBOH.
Like other 2C-X-NBOMe molecules, 25I-NBOMe is a derivative of the 2C family of phenethylamines described by chemist Alexander Shulgin in his book PiHKAL. [17] [15] Specifically, 25I-NBOMe is an N-benzyl derivative of the phenethylamine molecule 2C-I, formed by adding a 2-methoxybenzyl (BnOMe) onto the nitrogen (N) of the phenethylamine backbone ...
25C-NBOMe (NBOMe-2C-C, 2C-C-NBOMe, Cimbi-82) is a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. 25C-NBOMe appeared on online vendor sites in 2010 but was not reported in the literature until 2011. [3]
It is the N-benzyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDBZ was first synthesized by Alexander Shulgin . In his book PiHKAL (Phenethylamines i Have Known And Loved) , the minimum dosage is listed as 150 mg, and the duration unknown.
Phenoxybenzamine is used as an anti-hypertensive due to its efficacy in reducing the vasoconstriction caused by epinephrine (adrenaline) and norepinephrine.Phenoxybenzamine forms a permanent covalent bond with adrenergic receptors.